Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Workers' Comp
Article
Transportation and translation: an unlikely but powerful duo
Recently, the Sounding Board sat down with Jim Begg, Vice President of National Accounts for Apricus, to talk about transportation and translation
Workers' Comp
Podcast
Understanding Mental Health Misconceptions in Workers’ Comp
Hello and welcome to the first of a four-part podcast compliment to the Mitchell | Genex | Coventry thought leadership eBook, Strategies for Co
Mitchell
News Release
FDA Approves Higher Dose Naloxone, Kloxxado
Naloxone has been known by different brand names over the years as the primary treatment of opioid overdose.
Workers' Comp
News Release
Mitchell | Genex | Coventry Signs Agreement to Acquire QualCare Alliance Networks Inc.
Deal will strengthen company's network in New Jersey
Workers' Comp
News Release
Risk & Insurance: How Bayne, Genex and Sikorsky Banded Together to Create an Optimal Return-to-Work Program
In this National Comp session, Sikorsky, a Lockheed Martin Company, shares their newly created program that significantly decreased an injure
Workers' Comp
News Release
Mitchell | Genex | Coventry agrees to acquire QualCare
Deal will strengthen company's network in New Jersey San Diego, CA — May 11, 2021 — Mitchell | Ge